Filing Details

Accession Number:
0001209191-23-003866
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-01-18 19:09:18
Reporting Period:
2023-01-13
Accepted Time:
2023-01-18 19:09:18
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1679363 Morphic Holding Inc. MORF Pharmaceutical Preparations (2834) 473878772
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1780270 William Devaul C/O Morphic Holding, Inc.
35 Gatehouse Drive, A2
Waltham MA 02451
General Counsel And Secretary No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-01-14 3,250 $0.00 24,908 No 4 M Direct
Common Stock Disposition 2023-01-14 1,169 $30.63 23,739 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy Common Stock) Acquisiton 2023-01-13 62,160 $0.00 62,160 $31.72
Common Stock Restricted Stock Unit Acquisiton 2023-01-13 43,800 $0.00 43,800 $0.00
Common Stock Restricted Stock Unit Acquisiton 2023-01-14 3,250 $0.00 3,250 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
62,160 2033-01-12 No 4 A Direct
43,800 No 4 A Direct
9,750 No 4 M Direct
Footnotes
  1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.
  2. The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
  3. The option vests as to 2.0833% of the total shares monthly, beginning February 13, 2023, with 100% of the total shares vested and exercisable on January 13, 2027, subject to the reporting person's provision of service to the issuer on each vesting date.
  4. The RSUs vest as to 25% of the total shares on each of January 13, 2024, January 13, 2025, January 13, 2026 and January 13, 2027, subject to the reporting person's provision of service to the issuer on each vesting date.
  5. The RSUs vest as to 25% of the total shares on each of January 14, 2023, January 14, 2024, January 14, 2025 and January 14, 2026, subject to the reporting person's provision of service to the issuer on each vesting date.